biopharma musculoskeletal disorders_4-30-2013
DESCRIPTION
Better cell cultures lower your research costs!-A common Neuromics' theme is harnessing the power of cells. The raw cost of the cells are often the biggest consideration. We encourage our customers to focus on true costs. These include the # number of cells (how many times can they be passaged?), culture viability (how long do the cells live) and bioactivity (how closely do cultures mimic in vivo behavior?). I would like to present a publication and presentation confirms our competitiveadvantage when analyzing true costs.TRANSCRIPT
1
Harnessing the Power of CellsTM
New Assays for
Musculoskeletal Disorders Drug Discovery
Executive Overview
1 4/30/2013 2
Solutions for Musculoskeletal Disease Research
Potent Umbilical Cord Blood Derived Human Mesenchymal Stem Cells Alternative to induced pluripotent and embryonic stem cells Phenotypically and morphologically stable through 50 population doublings
i.e. CD44, CD45,CD71 and CD105 expressing. Capacity to produce cell numbers required for high throughput & content screening
Differentiated Cells: Osteoblasts, Chondrocytes and Fibroblasts
Potent Media Low serum and clinical grade, serumfree expansion media Osteogenesis, chondrogenesis &adipogenesis media Stem cell basal media
MSCGroTM Media vs Lonza
3
Potent Cells and Media-Better Results=Lower Costs
2 4/30/2013
Our Media Keeps your Cells Going and Going “We tested the effects of MSCTMGro defined medium using several different lots of human adult primary stem cells and found that MSCGro supports a more robust proliferation rate than normal undefined media. This provided shorter doubling times and increased cellular yield, and maintained the cells in an undifferentiated state. We also found that MSCGro medium is stable under normal laboratory conditions for an extended time period compared to other defined media.” Ben Buehrer, VP and CSO, Zen-Bio
Images: (A) Human cord-blood MSCs were expanded in low-serum MSC-GroTM to confluence as shown here. (B) were differentiated in osteogenic MSC-GroTM. Early stage osteoblasts are shown here; the arrow shows early formation of mineralized matrix. (C)&(D) Mature osteoblasts stained positive for Alizarin red. Phase contrast image at 200 x, scale bar is 50 mmeters.
3 4/30/2013 4
Potent Cells and Media-Summary
Cells are differentiated from human MSCs- Competitive to IPSCs since there is no
reprogramming nor epigenetic issues intrinsic to IPSCs
Cost-effective due to manufacturing scalability Direct purchase without licensing requirement
Highly experienced team with extensive technical and biopharma partnership experience.
Cell therapy application as well as discovery.
4 4/30/2013 5
Capabilities meet HCS/HTS Requirements
Cost-effective materials to meet target per well costs
Human cells reduce false positives vs. animal tissues
Cells express proteins of interest. Verification assays provided based on specific requirements.
Readily scalable: Identical phenotype/genotype from pilot to screening mode.
Co-culture capability for custom assays. E.g., chondrocyte/osteoblasts
5 4/30/2013 6
Evaluation Process
Confidential discussion of Specific Disorder, Therapeutic Target(s) and cell based assay requirements.
Design pilot assay with deliverables and milestones Review milestone data vs requirements Revise assay as needed Determine final assay configuration.
Determine scale up requirements Cost targets Material and deliverables Evaluate progress vs plans and adjust accordingly
Position capabilities for future projects
Draft 1 04-2013-3 7
Contacts
Technical and Consulting:Dr. Jim MusickPresidentVitro [email protected](303) 999-21304621 Technology Drive Golden, CO 80403
Sales/Proposal ProcessPete [email protected] West 74ths StreetEdina, MN 55439